Atossa Therapeutics, Inc.
ATOS
$2.40
-$0.12-4.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.32% | 56.31% | 40.88% | 30.54% | -0.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.83% | 33.13% | 59.92% | 44.89% | 27.23% |
| Operating Income | 3.83% | -33.13% | -59.92% | -44.89% | -27.23% |
| Income Before Tax | -0.81% | -42.74% | -72.32% | -20.22% | -39.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.81% | -42.74% | -72.32% | -20.22% | -39.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.81% | -42.74% | -72.32% | -20.22% | -39.25% |
| EBIT | 3.83% | -33.13% | -59.92% | -44.89% | -27.23% |
| EBITDA | 3.83% | -33.14% | -59.96% | -44.91% | -27.25% |
| EPS Basic | 2.44% | -42.74% | -68.90% | -17.06% | -35.36% |
| Normalized Basic EPS | 2.44% | -42.73% | -68.89% | -53.29% | -35.39% |
| EPS Diluted | 2.44% | -42.74% | -68.90% | -17.06% | -35.36% |
| Normalized Diluted EPS | 2.44% | -42.73% | -68.89% | -53.29% | -35.39% |
| Average Basic Shares Outstanding | 3.32% | 0.00% | 2.02% | 2.70% | 2.87% |
| Average Diluted Shares Outstanding | 3.32% | 0.00% | 2.02% | 2.70% | 2.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |